Skip to main content
Medexus Pharmaceuticals Inc. logo

Medexus Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · MDP ISIN · CA58410Q2036 LEI · 8945002TBEYY0HLH1M19 TSX Manufacturing
Open in API
Filings indexed 638 across all filing types
Latest filing 2023-08-17 Regulatory Filings
Country CA Canada
Listing TSX MDP

About Medexus Pharmaceuticals Inc.

https://www.medexus.com/en_US

Medexus Pharmaceuticals, Inc. is an innovative specialty pharmaceutical company engaged in the development and commercialization of treatment solutions. The company utilizes a highly scalable North American business model, leveraging a fully integrated infrastructure encompassing commercial operations, supply chain, regulatory affairs, and a dedicated salesforce. Medexus focuses on building a portfolio of specialty and rare disease products across key therapeutic areas, including hematology, hematology-oncology, allergy, dermatology, and rheumatology. Its mission is to deliver quality healthcare products to patients and healthcare professionals.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 85% confidence The document is a press release announcing the presentation of clinical study data on the efficacy and safety of IXINITY in pediatric patients with hemophilia B. It details study results, safety data, and regulatory status including FDA review of a supplemental Biological License Application. The content is focused on clinical trial outcomes and product information rather than financial results, management changes, or regulatory filings. It is not a financial report, earnings release, or regulatory filing. It is a corporate announcement of clinical study results and regulatory progress, typical of a Capital/Financing Update or general corporate news. However, since it does not discuss fundraising, capital structure changes, or financing activities, it does not fit the Capital/Financing Update category. It is also not a Regulatory Filing as it is a press release rather than a formal regulatory submission. The best fitting category is Regulatory Filings (RNS) as a fallback for miscellaneous corporate announcements that do not fit other categories, especially since it is a news release about clinical data and regulatory review status.
2023-08-17 English
News release - English.pdf
Interim / Quarterly Report Classification · 95% confidence The document is a detailed announcement of Medexus Pharmaceuticals' fiscal Q1 2024 financial results, including revenue, EBITDA, net income, and operational highlights. It contains substantive financial data and analysis for the quarter ended June 30, 2023. It also mentions a conference call to discuss these results. The document is approximately 15,000 characters long, indicating it is a full report rather than a brief announcement or a certification. The content aligns with a quarterly financial report containing actual financial statements and management discussion. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2024
2023-08-10 English
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 100% confidence The document contains detailed unaudited condensed interim consolidated financial statements for the three-month period ended June 30, 2023. It includes interim consolidated statements of financial position, income, comprehensive income, and changes in shareholders' equity. The presence of actual financial data and the specific interim period indicate this is a quarterly or interim financial report. The document length is substantial (15,000 characters), and it is not merely an announcement or certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q1 2024
2023-08-09 English
Interim MD&A - English.pdf
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Management’s Discussion & Analysis' (MD&A) for the three-month period ended June 30, 2023. It contains detailed financial discussion, operational highlights, liquidity, capital resources, risk factors, and non-GAAP measures. The period covered is a quarter, and the document includes substantive financial data and analysis. The MD&A is a management report explaining financial results and business trends for an interim period. Therefore, this document fits the category of an Interim / Quarterly Report (IR). Q1 2024
2023-08-09 English
52-109F2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a Form 52-109F2 Certification of Interim Filings by the CFO of Medexus Pharmaceuticals Inc. It certifies the review and fair presentation of the interim financial report and interim MD&A for the period ended June 30, 2023. The content is primarily an officer certification regarding the interim filings, controls, and procedures, without containing actual financial statements or substantive financial data. According to the Certification Rule, such certification documents should be classified as Regulatory Filings (RNS) rather than as the interim report itself (IR). The document length is 3399 characters, which is relatively short and consistent with a certification letter rather than a full interim report.
2023-08-09 English
52-109F2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a Form 52-109F2 Certification of Interim Filings by the CEO of Medexus Pharmaceuticals Inc. It certifies the review and fair presentation of the interim financial report and interim MD&A for the period ended June 30, 2023. The document is primarily an officer certification letter confirming the accuracy and completeness of the interim filings, without containing the actual financial statements or substantive financial data itself. According to the Certification Rule, such certification documents should be classified as Regulatory Filings (RNS) rather than as the interim report (IR) itself. The document length is 3286 characters, which is relatively short and consistent with a certification letter rather than a full interim report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2023-08-09 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.